TENAX Therapeutics
Clinical Laboratories
Why pick this one
Tenax develops TNX-103, an oral levosimendan formulation targeting PH-HFpEF, a condition with no currently approved treatments.
Best for
- Researchers focused on PH-HFpEF
- Potential clinical-trial or therapeutic-development collaborators in pulmonary vascular disease
- Heart failure and cardiovascular drug-development initiatives
Look elsewhere if
- Routine clinical laboratory testing
- Immediate patient treatment or prescription fulfillment
- Approved PH-HFpEF therapies
Specialties
- PH-HFpEF therapeutic development
- TNX-103 oral levosimendan development
- Pulmonary vascular disease drug development
- Cardiovascular drug development
What makes them different
- Develops TNX-103, an oral formulation of levosimendan
- Targets pulmonary hypertension resulting from heart failure with preserved ejection fraction
- Levosimendan is authorized for intravenous use in 60 countries
- Development strategy is guided by heart failure and lung disease experts
- Chief Medical Officer Stuart Rich is a pulmonary vascular disease specialist and Professor Emeritus at Northwestern University Feinberg School of Medicine
Distilled from this business's own website.
Contact & Location
- Address
- 101 Glen Lennox Dr Ste 300, Chapel Hill, NC 27517
- Phone
- 9198552100
- Website
- https://tenaxthera.com/
Services
- Clinical-stage drug development
- Clinical trial development
- Therapeutic research